Answers are grounded in this paper and cite their sources.
581G mutations associated with higher-level resistance were seen at multiple sites, although prevalence did not clearly increase over time. Overall, changes were consistent with the selective pressure of the national treatment regimen, artemether-lumefantrine, with increased sensitivity to chloroquine, and with poor efficacy of antifolates. Strong evidence for resistance to artemisinins was not seen. Continued surveillance of markers that predict antimalarial drug sensitivity is warranted.
No takes yet. Share an insight, caveat, or question.
Asua et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: